[Psychosomatic ratios and their correction in the autonomic dysfunction of the sinus node].
The study was undertaken to examine the ratio of mental to somatic disorders in patients with autonomic sinus nodal dysfunction (ASND) and the capacities of correction of revealed disorders with the atypical benzodiazepine drug clonazepam. Thirty-two patients with ASND were examined. The diagnosis of ASND was verified by 24-hour ECG monitoring and transesophageal atrial pacing, by performing autonomic cardiac block with atropine and obsidan. In addition to physical examination, heart rhythm variability was studied during relaxed and intensive wake; psychological studies using the conventional tests were conducted, and autonomic disorders were explored by means of original scored somatic, hyperventilation) questionnaires. After examination, the patients received a 1.5-to-2-month course of therapy with clonazepam in a daily dose of 1.5-2 mg. The study has revealed that clinical symptomatology in ASND is greatly determined by psychosomatic disorders. ASND was marked by anxious depressions in combination with inadequate peripheral (to a greater extent, sympathetic) neurovegetative exposures with the simultaneous activation of cerebral ergotropic effects. The use of clonazepam in ASND greatly improved its clinical picture, by eliminating, in the overwhelming majority of cases, clinical symptoms, including rhythm and conduction disturbances that are characteristic of ASND.
Nedostup
A V
AV
Fedorova
V I
VI
Kazikhanova
A A
AA
D000328:Adult; D002998:Clonazepam / Q000627:therapeutic use; D004562:Electrocardiography; D005260:Female; D018757:GABA Modulators / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011602:Psychophysiologic Disorders / Q000175:diagnosis / Q000188:drug therapy; D012804:Sick Sinus Syndrome / Q000175:diagnosis / Q000188:drug therapy
D018757:GABA Modulators; D002998:Clonazepam